Korean and Swiss companies will combine in the fight against cancer


Аvera Allen, Deputy Editor In Chief

Date: 12.03.2021

Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates

Genome & Company, a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research collaboration for the discovery of innovative cancer therapies in the expanding antibody-drug conjugates (ADC) class.

This research collaboration has been undertaken with the goal of further exploiting this new therapeutic class, potentially offering cancer patients future treatments that efficiently target cancer cells while avoiding impact on healthy tissues.

The collaboration between the two companies is built on the rapidly expanding Genome & Company’s novel target-based oncology drug pipeline and Debiopharm’s proven track record in oncology. The Swiss company has developed two standards of care in colorectal cancer (oxaliplatin) and in prostate cancer (triptorelin).

In order to accelerate the discovery of innovative tumor-specific treatments, both specialty companies are combining their individual expertise for the development of an optimal ADC candidate based on three important criteria: the target, the cytotoxic payload, and the linker. Specifically, Genome & Company, having generated several antibodies against novel oncology targets discovered based on its own drug development platform, GNOCLE ™ and will now be armed with Debiopharm’s Multilink ™ technology to deliver cytotoxic payloads to tumor cells. Multilink ™ is a unique and innovative technology in that it allows the loading of multiple and different payloads on an antibody. With Debiopharm, Genome & Company will conduct follow-up discussions on the clinical development and the licensing of newly discovered ADC candidates.

By Аvera Allen | Linkedin

Views: 19

Leave a request

Select option
Thank you, application submitted.